Novartis Ag ADR (NVS) Stock Price, Quote & News

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CD...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 41 61 324 11 11

Fax: 41 61 324 80 01

Website: www.novartis.com

Address:

Lichtstrasse 35, Basel, Switzerland

LatestInformation Feb. 4 at 1:07 PM

B. Riley Updates • $TGTX → Buy | PT $55 • $NVS / $RHHBY → coverage comments included B. Riley highlights key catalysts and outlook for these names in its latest note. Will share deeper takeaways as the full note is digested. Click to view @LatestInformation .to get the latest information.

0 · Reply

Quantumup Feb. 4 at 12:32 PM

B Riley reiterated $TGTX Buy/$55. $NVS $RHHBY Here's what B Riley had to say in its note:

0 · Reply

Quantumup Feb. 3 at 7:59 PM

BofA⬆️ $TVTX's PT to $44 from $43 and reiterated at a Buy after noting its thoughts ahead of 4Q earnings. $NBI $VERA $NVS $PFE Here's what BofA said in its note:

0 · Reply

Quantumup Feb. 2 at 12:49 PM

TD Cowen⬆️ $PVLA's PT to $190 from $133 and reiterated at a Buy rating. $NVS $PFE $TEVA TD Cowen said in its note: PVLA held a successful BTD advice meeting for QTORIN rapa in cVM v. recently and intends to file for BTD shortly. The meeting was attended by sr. FDA division leadership who heard strongly supportive KOL opinion of QTORIN rapa's efficacy in cVM. We have high conviction QTORIN rapa will receive BTD in cVM, which could allow FDA alignment on a single-arm Ph3 design, expediting data and approval.

0 · Reply

GJ_Rockabilt Jan. 30 at 3:32 PM

$NVS Today is last day to sign up for FREE TPST Warrants with every Share of Cancer fighting $TPST . Acquisition in process. Do your own Due Diligence. I want to see NVS get ahold of this. That's$TPST !

1 · Reply

Quantumup Jan. 29 at 11:44 AM

Oppenheimer⬆️ $DNTH's PT to $125 from $62 and reiterated at Outperform. $RNAC $ARGX $NVS AZN $VRTX TAK Oppenheimer said in its note: Dianthus shares have jumped off the starting line this year, up 22% vs. XBI's 5% following CEO Marino Garcia's commentary at January's annual healthcare conference on potential superiority vs. competitor complement inhibitors, and pricing expectations. We caught up with management ahead of the 2026 setup and see substantial value creation ahead. Catalysts begin with mid-year update on claseprubart's Phase 3 CIDP interim analysis followed by Phase 2 MMN data plus a first-look at DNTH212 in healthy volunteers in 2H26. We see little current value assigned to '212/MMN, and despite substantial share appreciation since the MG look, we believe DNTH shares are just beginning their ascent as comfort builds around potentially superior CIDP/MMN profiles, and as visibility into DNTH212's total product profile grows.

0 · Reply

clan Jan. 29 at 5:03 AM

$NVS $ABBV $RHHBY Who here knew there is an INHALABLE mealtime insulin?!? Holy smokes! 😲 No shooting up at meals! ❤️

0 · Reply

Quantumup Jan. 28 at 1:28 PM

Evercore ISI⬆️ $VRDN's PT to $45 from $44 and reiterated at an Outperform rating. $AMGN $IMVT - $ROIV $NVS TEVA Here's what Evercore ISI said in its note: https://x.com/Quantumup1/status/2016502597268471892?s=20

0 · Reply

Estimize Jan. 28 at 11:00 AM

Wall St is expecting 2.16 EPS for $NVS Q1 [Reporting 04/28 BMO] http://www.estimize.com/intro/nvs?chart=historical&metric_name=eps&utm_cont

0 · Reply

fred898w Jan. 28 at 6:51 AM

$NVS overvalued

0 · Reply

Novartis Sales Rise Despite Generic Drug Competition in U.S.

Feb 4, 2026, 1:12 AM EST - 8 hours ago

Novartis expects low single-digit decline in 2026 operating profit

Feb 4, 2026, 1:00 AM EST - 8 hours ago

Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025

Jan 22, 2026, 2:45 PM EST - 12 days ago

Novartis CEO on impact of 'most favored nation' drug pricing

Jan 22, 2026, 12:03 PM EST - 12 days ago

Novartis CEO Vas Narasimhan: ‘We really should be talking about out-of-pocket costs' in the U.S.

Jan 21, 2026, 2:00 AM EST - 14 days ago

Novartis CEO: Confident we are shielded from any further U.S. tariffs

Jan 20, 2026, 5:14 AM EST - 15 days ago

Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC

Jan 20, 2026, 5:10 AM EST - 15 days ago

Novartis expects to eliminate US tariff exposure by mid‑2026, CEO tells CNBC

Jan 13, 2026, 3:07 PM EST - 21 days ago

Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset

Jan 12, 2026, 2:56 PM EST - 22 days ago

Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 1:39 PM EST - 22 days ago

Novartis eyes more bolt-on acquisitions, CEO says

Jan 12, 2026, 9:43 AM EST - 22 days ago

SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs

Jan 9, 2026, 10:30 AM EST - 25 days ago

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Dec 31, 2025, 6:08 AM EST - 5 weeks ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

GSK LLY PFE SNY

Dec 28, 2025, 4:09 AM EST - 5 weeks ago

Novartis: A Mispriced Hedge In A Crowded Equity Market

Dec 19, 2025, 4:09 PM EST - 6 weeks ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK AMGN GILD SNY

Dec 19, 2025, 3:14 PM EST - 6 weeks ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GILD GSK MRK SNY

Dec 19, 2025, 2:34 PM EST - 6 weeks ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GILD GSK MRK SNY

Dec 19, 2025, 2:30 PM EST - 6 weeks ago

Novartis and US government reach agreement on lowering drug prices in the US

Dec 18, 2025, 4:30 AM EST - 6 weeks ago

Novartis, Roche back US efforts to lower drug costs amid talk of pricing deal

Dec 17, 2025, 4:11 PM EST - 6 weeks ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN AZN BMY LLY PFE

Dec 17, 2025, 1:14 PM EST - 6 weeks ago

Novartis, Roche near US drug price deal, Bloomberg News reports

Dec 17, 2025, 9:00 AM EST - 7 weeks ago

Salesforce's Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally

CRM

Dec 12, 2025, 7:00 AM EST - 7 weeks ago

Novartis breaks ground on flagship manufacturing hub in North Carolina

Dec 9, 2025, 2:32 PM EST - 2 months ago

Novartis' Investigational Drug Reports Longer Disease Control In Patients With Rare Blood Disorder

Dec 9, 2025, 7:51 AM EST - 2 months ago

Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster

Dec 9, 2025, 7:30 AM EST - 2 months ago

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

Dec 9, 2025, 7:15 AM EST - 2 months ago

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

Dec 9, 2025, 3:00 AM EST - 2 months ago

Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases

Dec 1, 2025, 12:53 PM EST - 2 months ago

Novartis AG (NVS) Discusses Social Impact, Global Health Initiatives, and Sustainability Strategy Transcript

Nov 25, 2025, 10:14 AM EST - 2 months ago

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

Nov 25, 2025, 4:02 AM EST - 2 months ago

Novartis plans to cut up to 550 jobs at Swiss facility

Nov 25, 2025, 1:15 AM EST - 2 months ago

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

Nov 24, 2025, 10:21 PM EST - 2 months ago

Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community

Nov 24, 2025, 5:26 PM EST - 2 months ago

FDA approves Novartis' gene therapy for rare muscle disorder

Nov 24, 2025, 5:16 PM EST - 2 months ago

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

Nov 21, 2025, 5:53 PM EST - 2 months ago

Novartis AG (NVS) Shareholder/Analyst Call Transcript

Nov 20, 2025, 12:43 PM EST - 2 months ago

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts

Nov 20, 2025, 1:51 AM EST - 2 months ago

Novartis Expects Steady Sales Growth Through 2030

Nov 20, 2025, 1:09 AM EST - 2 months ago

Novartis targets 5%-6% annual sales growth until 2030 on key drugs

Nov 20, 2025, 1:00 AM EST - 2 months ago

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Nov 19, 2025, 1:51 PM EST - 2 months ago

Novartis to build manufacturing hub in North Carolina, creating 700 jobs

Nov 19, 2025, 12:30 PM EST - 2 months ago

Novartis announces plans to build flagship manufacturing hub in North Carolina

Nov 18, 2025, 8:25 AM EST - 2 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK JNJ

Nov 17, 2025, 8:30 AM EST - 2 months ago

The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet

ATNM

Nov 12, 2025, 5:07 PM EST - 2 months ago

New, effective anti-malaria drug could help fight rising resistance, says Novartis

Nov 10, 2025, 9:34 AM EST - 3 months ago

Novartis opens new plant in California to make cancer drugs

Nov 4, 2025, 1:15 AM EST - 3 months ago

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

Nov 3, 2025, 8:00 AM EST - 3 months ago

Meharry and Novartis Partner on HEART Initiative for Healthier Communities

Oct 30, 2025, 4:46 PM EDT - 3 months ago

Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript

LatestInformation Feb. 4 at 1:07 PM

0 · Reply

Quantumup Feb. 4 at 12:32 PM

B Riley reiterated $TGTX Buy/$55. $NVS $RHHBY Here's what B Riley had to say in its note:

0 · Reply

Quantumup Feb. 3 at 7:59 PM

BofA⬆️ $TVTX's PT to $44 from $43 and reiterated at a Buy after noting its thoughts ahead of 4Q earnings. $NBI $VERA $NVS $PFE Here's what BofA said in its note:

0 · Reply

Quantumup Feb. 2 at 12:49 PM

0 · Reply

GJ_Rockabilt Jan. 30 at 3:32 PM

1 · Reply

Quantumup Jan. 29 at 11:44 AM

0 · Reply

clan Jan. 29 at 5:03 AM

$NVS $ABBV $RHHBY Who here knew there is an INHALABLE mealtime insulin?!? Holy smokes! 😲 No shooting up at meals! ❤️

0 · Reply

Quantumup Jan. 28 at 1:28 PM

0 · Reply

Estimize Jan. 28 at 11:00 AM

Wall St is expecting 2.16 EPS for $NVS Q1 [Reporting 04/28 BMO] http://www.estimize.com/intro/nvs?chart=historical&metric_name=eps&utm_cont

0 · Reply

fred898w Jan. 28 at 6:51 AM

$NVS overvalued

0 · Reply

OfficialStocktwitsUser Jan. 28 at 12:27 AM

$NVS RSI: 75.19, MACD: 3.5166 Vol: 3.80, MA20: 142.94, MA50: 136.51 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Quantumup Jan. 27 at 2:00 PM

JPMorgan reiterated $VERA Overweight/$96 TVTX OTSKY $NVS JBIO $VRTX RHHBY IONS $AZN $TAK JPMorgan said in its note: We continue to see atacicept as well positioned in the IgAN B-Cell modulator space and still see significant upside in VERA shares (as competitive readouts occur, we see the potential for VERA shares to grind higher to a more appropriate probability-adjusted level, which is nearly double from current levels based on our model).

0 · Reply

Quantumup Jan. 26 at 12:16 PM

H.C. Wainwright⬆️ $SRRK's PT to $58, reitd at Buy/said, Recent KOL feedback from neurologists (n=3), reinforced by management's latest regulatory and commercial updates, has further increased our confidence in apitegromab's launch trajectory. $BIIB $RHHBY $NVS H.C. Wainwright additionally said: https://x.com/Quantumup1/status/2015759886731124836?s=20

0 · Reply

Quantumup Jan. 26 at 11:25 AM

Oppenheimer⬆️ $RLAY: We are upgrading shares of Relay Therapeutics to Outperform (prior Perform) — with a $14 PT — because we believe that gedatolisib's upcoming VIKTORIA-1 readout could be a tailwind for mutant-selective inhibitors like zovegalisib. [ $CELC $NVS ] Bottom line: We believe VIKTORIA-1 will underperform expectations, and may even fail. We think anything less than "teenage" mPFS for the gedatolisib triplet would create a beatable bar for Relay, who is developing a competing triplet with zovegalisib. We think gedatolisib looks a lot like everolimus, and everolimus underperforms in PI3K. Relay shares have struggled since October when VIKTORIA-1's wild-type cohort came out and exceeded expectations. We believe that duplicating that success in PI3K-mutant patients will be more challenging for gedatolisib, especially given the recent precedent set by alpelisib in the EPIK-B5 trial (7.4-months mPFS).

0 · Reply

JuggernautRaider Jan. 24 at 2:00 PM

$ALT the old CEO of Geron sounds like a bum. The new CEO worked at $NVS for years and was the new CEO of Immuneeics when they sold for a premium to $GILD which makes me more bullish. Their current indication is very niche - a positive OS readout in 2L+ myelofibrosis 🧐 $BMY would also be a likely acquirer with their hem/onc portfolio and patent cliffs

1 · Reply

SparkyReturns Jan. 22 at 4:41 PM

$AZN Biotech investors should take a look at this tiny company that is saving lives and creating value. Might be scooped up by big pharma. Look at the incredible setup for Seastar (ICU): 8M MC, with a TAM in the Billions (read that again); 2M NET revenue this year expected; 90% margins; Ramping up a product which will potentially/likely become Standard of Care for a number of conditions involving hyper-inflammation and sepsis (AKI, Cardiorenal, burn victims, transplant patients); Saves lives of AKI patients and ELIMINATES dialysis dependency; Total addressable market anywhere from 2B-20B; Zero debt; Pivotal adult AKI study to be completed in 12-15 months, possibly sooner; Being used at Mayo Clinic, Cinci Childrens, CHOP (Philadelphia), many more; 6 Breakthrough Device Designations (most ever); Cash burn reducing due to ramped up pediatric sales for longer runway; So, 8M MC for a company that will be worth Billions in a few years. $NVS $GILD $VRTX $SNY

0 · Reply

SparkyReturns Jan. 22 at 3:39 PM

$PFE Here's an idea for biotech investors. Big Pharma should pay attention to this tiny company that is saving lives and creating value. Look at the incredible setup for Seastar (ICU). 8M MC, with a TAM in the Billions (read that again); 2M NET revenue this year expected; 90% margins; Ramping up a product which will potentially/likely become Standard of Care for a number of conditions involving hyper-inflammation and sepsis (AKI, Cardiorenal, burn victims, transplant patients); Saves lives of AKI patients and ELIMINATES dialysis dependency; Total addressable market anywhere from 2B-20B; Zero debt; Pivotal adult AKI study to be completed in 12-15 months, possibly sooner; Being used at Mayo Clinic, Cinci Childrens, CHOP (Philadelphia), many more; 6 Breakthrough Device Designations (most ever); Cash burn reducing due to ramped up pediatric sales for longer runway; So, 8M MC for a company that will be worth Billions in a few years. $JNJ $TAK $NVS $MRK

0 · Reply

OpenOutcrier Jan. 20 at 1:42 PM

$NVS (+0.1% pre) Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC https://ooc.bz/l/90063

0 · Reply

kindness123 Jan. 20 at 12:39 PM

$NVS https://finance.yahoo.com/news/novartis-expects-eliminate-us-tariff-101029835.html

0 · Reply

ZacksResearch Jan. 19 at 6:09 PM

Big milestone for $NVS — breakthrough status is a serious signal 🚀 The FDA just granted Breakthrough Therapy designation to Novartis’ ianalumab for Sjogren's disease, accelerating its path forward, with global filings planned to start in 2026. That’s meaningful regulatory momentum. See what this breakthrough could mean next 👉 https://www.zacks.com/stock/news/2819576/novartis-ianalumab-wins-breakthrough-therapy-tag-for-sjogrens-disease?cid=sm-stocktwits-2-2819576-teaser-29524&ADID=SYND_STOCKTWITS_TWEET_2_2819576_TEASER_29524

0 · Reply

ZacksResearch Jan. 19 at 5:09 PM

$NVS secures FDA Breakthrough Therapy designation for ianalumab — a potential new treatment for Sjogren’s disease? 💥 🧬 Novel dual-action monoclonal antibody 📈 Phase III trials show significant disease activity reduction 📈 Shares up 48% over the past year compared to the industry’s 24.1% rise Discover the full potential here 👉 https://www.zacks.com/stock/news/2819576/novartis-ianalumab-wins-breakthrough-therapy-tag-for-sjogrens-disease?cid=sm-stocktwits-2-2819576-body-29526&ADID=SYND_STOCKTWITS_TWEET_2_2819576_BODY_29526

0 · Reply

Quantumup Jan. 16 at 6:23 PM

Cantor reiterated Top Pick $VERA Overweight; $100. $TVTX $NVS OTSKY $JBIO VRTX AZN $IONS RHHBY Here's what Cantor had to say: We caught up with VERA, a "Top Pick," and discussed atacicept's (APRIL/BAFF inh; BTD) potential approval in IgA nephropathy (IgAN) and commercial launch preparations... Our overall takeaway is that all the pieces are in place for a successful regulatory outcome as VERA lays the framework for a strong commercial launch.

0 · Reply

Market Cap	314.07B
Revenue (ttm)	51.72B
Net Income (ttm)	11.94B
EPS (ttm)	N/A
PE Ratio	16.68
Forward PE	16.41
Profit Margin	23.09%
Debt to Equity Ratio	0.67

Volume	3,522,400
Avg Vol	1,698,850
Day's Range	N/A - N/A
Shares Out	2.11B
Stochastic %K	67%
Beta	0.51
Analysts	Sell
Price Target	$133.72